
AIM ImmunoTech AIM
$ 0.41
-6.47%
Quarterly report 2026-Q1
added 05-15-2026
AIM ImmunoTech Interest Expense 2011-2026 | AIM
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense AIM ImmunoTech
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 812 K | 585 K | 1.07 M | 629 K | 67 K | 672 K | 427 K | 201 K | - | - | 3 K | 11 K | 16 K | 24 K | 41 K | 11 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.07 M | 3 K | 326 K |
Quarterly Interest Expense AIM ImmunoTech
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 304 K | 148 K | 149 K | 124 K | - | 202 K | 179 K | 72 K | - | 294 K | 318 K | 199 K | - | 172 K | 79 K | - | - | 67 K | 19 K | 50 K | - | 51 K | 249 K | 322 K | - | - | - | 4.28 K | - | 4.3 M | - | - | - | - | - | - | - | - | - | - | - | 1 K | 2 K | 2 K | - | - | - | - | 165 K | 85 K | 349 K | 49 K | 719 K | -68 K | -33 K | 11 K | -82 K | 21 K | 12 K | 6 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.3 M | -82 K | 244 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
9.34 K | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
262 K | - | 1.35 % | $ 17.8 M | ||
|
Coherus BioSciences
CHRS
|
9 M | $ 1.59 | -3.64 % | $ 186 M | ||
|
AgeX Therapeutics
AGE
|
51 K | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
Celldex Therapeutics
CLDX
|
927 K | $ 31.43 | -0.85 % | $ 2.09 B | ||
|
Deciphera Pharmaceuticals
DCPH
|
16.4 M | - | - | $ 2.18 B | ||
|
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B | ||
|
BioNTech SE
BNTX
|
14.2 M | $ 95.95 | 2.69 % | $ 23.2 B | ||
|
Athira Pharma
ATHA
|
1.24 M | - | - | $ 269 M | ||
|
Compugen Ltd.
CGEN
|
281 K | $ 2.63 | -5.4 % | $ 246 M | ||
|
Galera Therapeutics
GRTX
|
11.4 M | - | -32.59 % | $ 7.61 M | ||
|
Berkeley Lights
BLI
|
910 K | - | -7.31 % | $ 87 M | ||
|
IMV
IMV
|
2.34 K | - | - | $ 13.1 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
354 K | - | -4.36 % | $ 27 M | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
2.15 M | - | - | $ 384 M | ||
|
Gracell Biotechnologies
GRCL
|
6.74 M | - | - | $ 3.37 B | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
CRISPR Therapeutics AG
CRSP
|
86.6 M | $ 56.18 | -0.35 % | $ 5.05 B | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
561 K | $ 3.35 | -0.3 % | $ 5.51 M | ||
|
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
1.44 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
-43 K | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
443 K | $ 21.46 | 0.09 % | $ 2.73 B | ||
|
Allena Pharmaceuticals
ALNA
|
-38 K | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-5.01 K | - | -11.43 % | $ 502 K |